source
- PepGen reports promising early results for myotonic dystrophy type 1 drug in six-patient trialPepGen announced that its experimental therapy for myotonic dystrophy type 1 showed the most encouraging early data yet in a small study. The trial involved six patients who received the drug for 1…
- Coherus Oncology cuts 30% of staff to focus on esophageal cancer comboCoherus Oncology announced another round of layoffs, reducing its workforce by about 30% as it narrows its development program. The cuts follow the presentation of phase 1b data on a combination o…